BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

ABSTRACTIntroduction B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent malignant tumor affecting children. While the majority of B-ALL patients (90%) experience successful recovery, early relapse cases of B-ALL continue to exhibit high mortality rates. MZ1, a novel inhibitor of Bromo...

Full description

Bibliographic Details
Main Authors: Li Ma, Jianwei Wang, Yang Yang, Jun Lu, Jing Ling, Xinran Chu, Zimu Zhang, Yanfang Tao, Xiaolu Li, Yuanyuan Tian, Zhiheng Li, Yongping Zhang, Xu Sang, Lihui Lu, Xiaomei Wan, Kunlong Zhang, Yanling Chen, Juanjuan Yu, Ran Zhuo, Shuiyan Wu, Jian Pan, Xiuxia Zhou, Yixin Hu, Shaoyan Hu
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Hematology
Subjects:
BET inhibitor
BRD4
MZ1
B-cell acute lymphoblastic leukemia
CCND3
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2247253

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2023.2247253

Similar Items